Blue Trust Inc. boosted its position in Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 31.3% during the fourth quarter, ...

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 484,666 shares of the biopharmaceutical company’s stock ...

The stock's fall snapped a three-day winning streak.

Shares of Catalyst Pharmaceuticals Inc. CPRX rose 1.34% to $23.40 Wednesday, on what proved to be an all-around favorable ...

Baird initiated coverage on Catalyst Pharmaceutical Partners (NASDAQ:CPRX) with an Outperform rating and set a price target ...

Fintel reports that on February 4, 2025, Baird initiated coverage of Catalyst Pharmaceuticals (NasdaqCM:CPRX) with a ...

Baird analyst Joel Beatty last night initiated coverage of Catalyst Pharmaceuticals (CPRX) with an Outperform rating and $28 price target ...

In a report released today, Jason Gerberry from Bank of America Securities reiterated a Hold rating on Amphastar Pharmaceuticals (AMPH – ...

The healthcare industry is set for growth due to advancements in targeted treatments and personalized care and the rapid ...

Scientists have made an advancement in the field of electrocatalysis. Their latest research sheds light on how catalysts can stay in unanticipated forms during the process of nitrate reduction. The ...

UC Santa Cruz has announced the Innovation Catalyst Grant proof-of-concept program awardees, showcasing the campus’s ...